Study on the synthesis of novel 5-substituted 2-[2-(pyridyl)ethenyl]-1,3,4-oxadiazoles and their acid–base interactions

Agnieszka Kudelko · Karolina Jasiak · Krzysztof Ejsmont

Received: 18 June 2014 / Accepted: 10 November 2014 / Published online: 20 December 2014
© The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract A series of novel 5-substituted 2-[2-(pyridyl)ethenyl]-1,3,4-oxadiazoles were efficiently synthesized by cyclocondensation of the appropriate 3-(pyridyl)acrylohydrazides with triethyl orthoesters in the presence of glacial acetic acid. The products were identified by means of spectroscopic methods and their $pK_A$ ionization constants were determined. The influence of substituents on the basicity of the pyridine system has been discussed.

Keywords Heterocycles · Basicity · Cyclizations · 1,3,4-Oxadiazoles · 3-(Pyridyl)acylohydrazides · $pK_A$ Ionization constants

Introduction

1,3,4-Oxadiazoles belong to the group of five-membered aromatic heterocycles, containing one oxygen and two nitrogen atoms. Many of these compounds exhibit a wide range of pharmaceutical and biological activities such as antibacterial, antiviral, anti-inflammatory, analgesic, or anticonvulsant [1–6]. Additionally, 1,3,4-oxadiazole derivatives act as potential agents in the treatment of cancer and AIDS [7–10]. They are also used extensively in agriculture as herbicides, fungicides, or insecticides [11, 12]. These heterocyclic molecules are applied in the production of heat-resistant polymers, blowing agents, optical brighteners, and anti-corrosion agents [13–16]. Conjugated $\pi$-electronic arrangements based on the electron-deficient 1,3,4-oxadiazole ring feature excellent electron-transporting properties with much higher quantum efficiency in comparison to conventional fluorescent emitters using silicon and its solid solutions (doped silicon). Therefore, they are used as monomers in the production of fluorescent emitters for organic light-emitting diodes, photovoltaic cells, scintillators, and photosensitive materials [13–16]. However, many of the previously investigated compounds applied in organic electronics suffer from their poor processability and low thermal and chemical stability. Due to these facts, the study on designing and synthesis of new organic conjugated materials whose physicochemical properties may be easily modified seems to be reasonable.

Synthesis of 1,3,4-oxadiazoles has been first described by Ainsworth in the 50s last century [17]. The most popular methods to synthesize 1,3,4-oxadiazole scaffold involve the use of $N,N'$-diacyldihydrazines or $N$-acylhydrazones (Scheme 1). Typically, cyclodehydration of $N,N'$-diacyldihydrazines is carried out using reagents such as PPA [18], $H_2SO_4$ [19], SOCl$_2$ [20, 21], POCl$_3$ [22, 23], $P_2O_5$ [24] (CF$_3$SO$_2$)$_2$O [25], BF$_3$·OEt$_2$ [26] or the Burgess reagent [27]. 1,3,4-Oxadiazole derivatives may also be prepared by oxidative cyclization of $N$-acylhydrazones with oxidizing agents such as CAN [28], KMnO$_4$ [29], FeCl$_3$ [30], Br$_2$ [31], PbO$_2$ [32], chloramine T [33], HgO/I$_2$ [34], hyper-valent iodine reagents [35–41]. One-pot syntheses of these compounds from acid hydrazides with carboxylic acids [42] or orthoesters [43–45] in the presence of an acidic catalyst have also been reported. Other synthetic routes involve acylation and subsequent ring opening and ring closure of starting tetrazoles [46, 47], heterocyclization of
semicarbazide, thiosemicarbazide and selenosemicarbazide derivatives [48–50], as well as transformation of 1,2,4-oxadiazoles under the influence of UV radiation [51]. Recently, solid phase syntheses of arrangements based on the 1,3,4-oxadiazole fragment have also been described in the literature [52–56].

In continuation of our studies on the application of \( \alpha,\beta \)-unsaturated acid hydrazides in the synthesis of conjugated 2-[2-(aryl)ethenyl]-1,3,4-oxadiazole derivatives, we investigated structures possessing the pyridylethenyl moiety at the \( \alpha \) position [57]. Herein, we report the synthesis of three types of 3-(pyridyl)acyloxyhydrazides and their reactions with triethyl orthoesters. The presence of the acid-sensitive pyridyl fragment is particularly important because it allows the acid–base modification of the physical properties of the indicated structures which may serve as potential monomers for optoelectronics.

**Results and discussion**

Hydrazides of selected 3-(pyridyl)acrylic acids 5a–5c were used as precursors of 1,3,4-oxadiazole derivatives. These compounds were obtained from the appropriate commercially available heteroaromatic aldehydes, 2-pyridinecarboxaldehyde (1a), 3-pyridinecarboxaldehyde (1b), and 4-pyridinecarboxaldehyde (1c) according to a few-step procedure (Scheme 2).

In a typical synthetic procedure, the starting aldehydes were treated with malonic acid in pyridine in the presence of piperidine as a catalyst under Knoevenagel–Doebner reaction conditions. Condensation and successive decarboxylation of intermediate dicarboxylic acids occurred giving \( \alpha,\beta \)-unsaturated monocarboxylic acids, 3-(pyridyl)acrylic acids 2a–2c in high yields. The resulting acids were neutralized with potassium hydroxide to form the appropriate potassium salts 3a–3c which were then used in a one-pot, two-step synthesis, yielding acid hydrazides 5a–5c. First, the potassium salts 3a–3c were treated with ethyl chloroformate and finally excess amounts of hydrazine hydrate. The reaction conducted at low temperature in acetonitrile solution resulted in the formation of the desired hydrazides 5a–5c in satisfactory yields (73–79 %, Scheme 2). The same hydrazides 5a–5c were also prepared by the typical two-step transformation from the appropriate 3-(pyridyl)acrylic acids 2a–2c by esterification with methanol and thionyl chloride followed by treatment with hydrazine hydrate. The reaction conducted at low temperature in acetonitrile solution resulted in the formation of the desired hydrazides 5a–5c in satisfactory yields (73–79 %, Scheme 2). The same hydrazides 5a–5c were also prepared by the typical two-step transformation from the appropriate 3-(pyridyl)acrylic acids 2a–2c by esterification with methanol and thionyl chloride followed by treatment with hydrazine hydrate. However, the low yields of the final hydrazides 5a–5c (35–44 %) made the above synthetic procedure unattractive.

The resulting acid hydrazides 5a–5c were heated with an excess of triethyl orthoesters (\( R = \text{Me, Et, Ph} \); Scheme 3)
in glacial acetic acid, yielding a series of 2-[2-(pyridyl)ethenyl]-1,3,4-oxadiazoles \(6a-6i\) substituted at the 5-position with a phenyl or an alkyl group that have not previously been reported in the literature. The commercially available triethyl orthoesters play the dual role of the synthon introducing the methylene carbon atom and high-boiling solvent.

Generally, the reaction yields increased with the increasing bulk of substituent \(R\) on the orthoester. The best results were obtained in the case of derivatives with a phenyl or an alkyl group have not previously been reported in the literature. The commercially available triethyl orthoesters play the dual role of the synthon introducing the methylene carbon atom and high-boiling solvent.

The structures of new products were confirmed with elemental analysis and spectroscopic methods (\(^1\)H and \(^13\)C NMR, MS, UV, IR). In the series of 2-[2-(pyridyl)ethenyl]-1,3,4-oxadiazoles \(6a-6i\), the diagnostic signals in the \(^1\)H NMR spectra are two doublets with the coupling constants \(J = 16.4\) Hz associated with two protons of the ethylene group. The value of the coupling constants suggests that \(E\) geometric isomers of these compounds are formed in the reaction. The proton adjacent to pyridine ring at the \(\beta\) position to the 1,3,4-oxadiazole ring is seen in the range between 7.44 and 7.72 ppm, while the proton \(\alpha\)-CH equals appears at high fields in the range of 7.08–7.57 ppm. Interestingly, analysing the spectra of 2-[2-(pyridyl)ethenyl]-1,3,4-oxadiazoles \(6a-6c\), one should notice the characteristic ethylene \(\alpha\)-CH= and \(\beta\)-CH= proton shifts. These two protons are observed at a much lower field due to the neighbouring pyridine nitrogen atom. Furthermore, the two protons \(C_2^\alpha\)-H and \(C_6^\alpha\)-H of the phenyl group substituted at 5-position of the 1,3,4-oxadiazole ring of \(6c, 6f, \) and \(6i\) are shifted in the \(^1\)H NMR spectra to lower fields and appear as a doublet of doublets.

| Product | \(R\) | Reaction time/h | Yield a/% | M.p./°C |
|---------|-------|-----------------|-----------|---------|
| \(6a\)  | 2-Py  | 9.0             | 74        | 108–110 |
| \(6b\)  | 2-Py  | 8.0             | 81        | 50–51   |
| \(6c\)  | 2-Py  | 5.0             | 92        | 126–128 |
| \(6d\)  | 3-Py  | 10.0            | 69        | 116–118 |
| \(6e\)  | 3-Py  | 8.5             | 78        | 54–56   |
| \(6f\)  | 3-Py  | 6.0             | 88        | 169–171 |
| \(6g\)  | 4-Py  | 9.0             | 76        | 118–120 |
| \(6h\)  | 4-Py  | 8.0             | 84        | 62–65   |
| \(6i\)  | 4-Py  | 4.5             | 94        | 172–174 |

\(^a\) Yield with respect to the starting hydrazide \(5a-5c\)
in the range from 8.10 to 8.13 ppm. Such significant changes in the chemical shifts could result from the proximity of these atoms to the ring’s nitrogen and oxygen atoms. In the $^{13}$C NMR spectra of 1,3,4-oxadiazoles 6a–6i, the characteristic signals are peaks of ethylene carbon atoms α-CH= and β-CH=, which are observed in ranges of 112–114 ppm and 133–139 ppm, respectively. The ring carbon atom C2 is seen in the range between 163 and 166 ppm, while the location of the second carbon atom C5 depends on the type of the substituent and appears between 164 and 170 ppm.

To establish the structure of derivatives 6, X-ray analysis was also performed. The molecular structure of 5-phenyl-2-[2-(2-pyridyl)ethenyl]-1,3,4-oxadiazole (6c) and 5-phenyl-2-[2-(3-pyridyl)ethenyl]-1,3,4-oxadiazole (6f) with the atomic numbering scheme is shown in Fig. 1. Each of the analysed compounds consists of three rings: I (the pyridine ring containing atoms C8–C13), II (the oxadiazole ring containing atoms O1–C5), and III (the phenyl ring containing atoms C14–C19). The values of the I/II, I/III, and II/III dihedral angles are collected in Table 2. According to collected data, it was concluded that both molecules adopt coplanar conformation. The near planarity of the systems favours the formation of intramolecular hydrogen bonds and π-electron delocalization. The C–C bonds located between the aromatic rings (C2–C6, C6–C7, C7–C8, and C5–C14) exhibit intermediate values due to π-electron delocalization in the molecules. This effect is more pronounced in the more coplanar structure 6c.

The twist along the C2–C6, C7–C8, and C5–C14 bonds is illustrated by torsion angles and it is rather small in both compounds (Table 2). In the studied molecules, the remaining bond lengths and angles are normal and are in good agreement with the geometry of similar derivatives of 1,3,4-oxadiazole [58–60]. These structures are stabilized by two intramolecular hydrogen bonds C7–H7⋯O1 and C15–H15A⋯O1 (Table 3) which give rise to the five-membered ring systems in all cases and confirm existence of E geometrical form of both compounds.

Considering the fact that physical properties of compounds are also strongly dependent on their ability to acid–base interactions, the $pK_A$ values of 5-substituted 2-[2-(pyridyl)ethenyl]-1,3,4-oxadiazoles 6a–6i were determined (Table 4). The determination of the $pK_A$ dissociation constants was performed according to the spectrophotometric method of Albert and Serjeant [61] in 50% aqueous methanol solution ($10^{-5} \text{ M}$, room temperature) due to the low solubility of the examined compounds in water.
pKₐ values determined in aqueous methanol solution are lower about 0.6 pKₐ unit comparing with those determined in aqueous solution which is the result of different ionic products of these solvents. Absorption maxima of the 1,3,4-oxadiazole ions were selected as analytical wavelengths bearing in mind their considerable shifts relative to the maxima of the non-protonated forms. The conducted studies have shown that the 1,3,4-oxadiazol-2-ylethenyl moiety at positions 2, 3, or 4 of the pyridine ring causes an increase in acidity compared to the pKₐ value of the unsubstituted pyridine (Scheme 4) [62].

Generally, 2-[2-(pyridyl)ethenyl]-1,3,4-oxadiazoles 6a–6i are stronger acids than the corresponding vinylpyridine derivatives 9 (Scheme 4). This is probably the result of the presence of the electron-withdrawing 1,3,4-oxadiazole ring conjugated via an ethenyl linker to pyridine. This leads to the decreasing of the electron density of the ring nitrogen atom. Among the three series of pyridine substituted 1,3,4-oxadiazoles, 2-[2-(3-pyridyl)ethenyl]-1,3,4-oxadiazoles 6d–6f exhibit the most acidic properties, while the rest 6a–6c and 6g–6i show the similar acid–base activities. Analogical behaviour was observed in the case of differently substituted methylpyridine derivatives 8 (Scheme 4).

Conclusion

In conclusion, we have synthesized a series of novel 5-substituted 2-[2-(pyridyl)ethenyl]-1,3,4-oxadiazoles in the reactions of three types of differently substituted 3-(pyridyl)acrylohydrazides with triethyl orthoesters in glacial acetic acid. This easy and efficient method has the advantage of providing the desired products in high yields, which makes it a useful addition to the existing synthetic protocols. The presence of the acid-sensitive pyridyl fragment is particularly important because it allows the electronic properties modification of the indicated structures by acid–base interactions, which makes them especially attractive for optoelectronic applications.

Experimental

All solvents and reagents were purchased from commercial sources and were used without additional purification. Melting points were measured using a Stuart SMP3 melting point apparatus. Elemental analyses were performed with a
VaroEL analyser. UV spectra were recorded on a Jasco V-650 spectrophotometer. The $^1$H and $^{13}$C NMR spectra were recorded on an Agilent 400-MR spectrometer in DMSO-$d_6$, CDCl$_3$, or CD$_3$OD solutions using TMS as the internal standard. Thin-layer chromatography was performed on silica gel 60 F$_254$ (Merck) thin-layer chromatography plates using MeOH/CHCl$_3$ (1:4 v/v) as the mobile phase, FT-IR spectra were recorded between 4000 and 650 cm$^{-1}$ on an FT-IR Nicolet 6700 apparatus with a Smart iTR accessory. Mass spectra were obtained on a GC/MS Agilent Technologies 7890A/5975C System with triple axis detector using the EI technique (70 eV). The pK$_a$ ionization constants of 2-[2-(pyridyl)ethenyl]-1,3,4-oxadiazoles 6a–6i were determined by spectrophotometric method of Albert and Serjeant in 50 % aqueous methanol solutions (10$^{-5}$ M) at room temperature.

**General procedure for the synthesis of 3-(pyridyl)acrylic acids 2a–2c**

A mixture of 32.1 g pyridinecarboxaldehyde 1a–1c (0.30 mol) and 31.2 g malonic acid (0.30 mol) in a solution of 30 cm$^3$ pyridine and 1 cm$^3$ piperidine was heated in a steam bath and stirred for 2 h. After cooling to room temperature, the precipitate was collected by filtration, washed with H$_2$O and dried. The crude product was crystallized from a EtOH/H$_2$O mixture, yielding the corresponding pure 3-(pyridyl)acrylic acid 2a–2c.

3-(2-Pyridyl)acrylic acid (2a)

White solid; yield 42.0 g (94 %); m.p.: 201–203 °C (Ref. [63] 202–204 °C).

3-(3-Pyridyl)acrylic acid (2b)

White solid; yield 41.1 g (92 %); m.p.: 232–234 °C (Ref. [64] 232–235 °C).

3-(4-Pyridyl)acrylic acid (2c)

White solid; yield 42.9 g (96 %); m.p.: 277–279 °C (Ref. [65] 277–280 °C).

**General procedure for the preparation of 3-(pyridyl)acrylohydrazides 5a–5c**

The appropriate 3-(pyridyl)acrylic acid 2a–2c (14.9 g, 0.10 mol) was slowly added to a stirred solution of 5.6 g KOH (0.10 mol) in 100 cm$^3$ H$_2$O. The mixture was stirred for approximately 10 min and then concentrated using a rotary evaporator. The precipitate was washed with 2 × 50 cm$^3$ Et$_2$O, collected by filtration and air dried to give the corresponding crude potassium salt as a white solid: 18.1 g (97 %) 3a, 17.8 g (95 %) 3b, and 18.3 g (98 %) 3c.

To a stirred suspension of 16.8 g potassium salt 3a–3c (0.09 mol) in 100 cm$^3$ MeCN was added a 1 % solution of pyridine in 30 cm$^3$ MeCN and 9.8 g ethyl chloroformate (0.09 mol). The reaction mixture was agitated at 0 °C for 2 h and then slowly poured into a stirred, ice-cooled suspension of 9.0 g hydrazine hydrate (0.18 mol) in 100 cm$^3$ MeCN. After filtration, the filtrate was kept in an ice box overnight, then washed with 2 × 50 cm$^3$ saturated aqueous Na$_2$CO$_3$ solution, dried over MgSO$_4$, and concentrated using a rotatory evaporator. The crude product was purified by column chromatography with silica gel and an eluent of MeOH/CHCl$_3$ (1:4 v/v) to yield the 3-(pyridyl)acrylic acid hydrazides 5a–5c.

3-(2-Pyridyl)acrylohydrazide (5a, C$_8$H$_9$N$_3$O)

Yellow solid; yield 11.0 g (75 %); m.p.: 108–110 °C; $R_f = 0.31$ (MeOH/CHCl$_3$, 1:4 v/v); $^1$H NMR (400 MHz, DMSO-$d_6$): $\delta = 9.53$ (1H, s, NH), 8.58 (1H, d, $J = 4.0$ Hz, C6'-H), 7.80 (1H, t, $J = 7.6$ Hz, C4'-H), 7.54 (1H, d, $J = 7.6$ Hz, C3'-H), 7.45 (1H, d, $J = 15.6$ Hz, $\beta$-CH=), 7.34–7.31 (1H, m, C5'-H), 7.00 (1H, d, $J = 15.6$ Hz, $\alpha$-CH=), 4.51 (2H, br s, NH$_2$) ppm; $^{13}$C NMR (100.6 MHz, DMSO-$d_6$): $\delta = 164.0$ (CO), 153.0, 149.8, 137.6, 137.2, 124.2, 124.0, 123.9 ppm; IR (ATR): $\tilde{\nu} = 3,277, 3,176, 3,054, 3,026, 1,989, 1,659, 1,591, 1,486, 1,474, 1,437, 1,336, 1,305, 1,249, 1,218, 1,188, 1,126, 1,095, 1,048, 955, 928, 872, 876, 728, 676 cm$^{-1}$; UV–Vis (MeOH): $\lambda_{max}$ ($\varepsilon \times 10^{-3}$) = 291.0 (13.65), 250.0 (13.46), 201.0 (16.65) nm (mol$^{-1}$ dm$^3$ cm$^{-1}$); MS (EI, 70 eV): $m/z$ (%) = 163 (M$^+$, 18), 148 (22), 133 (79), 132 (100), 130 (27), 105 (21), 104 (92), 79 (40), 78 (65), 77 (13), 76 (10), 52 (15), 51 (30).

3-(3-Pyridyl)acrylohydrazide (5b)

Yellow solid; yield 10.7 g (73 %); m.p.: 128–130 °C (Ref. [66] 126 °C).

3-(4-Pyridyl)acrylohydrazide (5c)

Yellow solid; yield 11.6 g (79 %); m.p.: 149–151 °C (Ref. [67] 150–151 °C).

**General procedure for the synthesis of 5-substituted 2-[2-(pyridyl)ethenyl]-1,3,4-oxadiazoles 6a–6i**

The starting 3-(pyridyl)acrylohydrazide 5a–5c (1.63 g, 10.0 mmol) was added to a mixture of the appropriate triethyl orthoester (20.0 mmol) and 10 cm$^3$ glacial AcOH. The mixture was kept under reflux until the starting hydrazide was fully consumed (monitored by TLC, 4.5–10 h). After cooling, the excessive orthoester and AcOH were evaporated under reduced pressure. The crude products 6a–6i were crystallized from appropriate solvents.

5-Methyl-2-[2-(pyridyl)ethenyl]-1,3,4-oxadiazole (6a, C$_{10}$H$_9$N$_3$O)

White solid; yield 1.38 g (74 %); m.p.: 108–110 °C; $R_f = 0.66$ (MeOH/CHCl$_3$, 1:4 v/v); $^1$H NMR (400 MHz,
5-Ethyl-2-[2-(pyridyl)ethenyl]-1,3,4-oxadiazole

**6b, C_{11}H_{11}N_{3}O**

White solid; yield 1.63 g (81%); m.p.: 50–51 °C; \( R_f = 0.68 \) (MeOH/CHCl₃, 1:4 v/v); \(^1^H\) NMR (400 MHz, CD₃OD): \( \delta = 8.66 \) (1H, d, \( J = 4.0 \) Hz, C₂-H), 7.91 (1H, t, \( J = 7.6 \) Hz, C₄-H), 7.71 (1H, d, \( J = 7.6 \) Hz, C₃'-H), 7.66 (1H, d, \( J = 16.4 \) Hz, \( \beta\)-CH=), 7.55 (1H, d, \( J = 16.4 \) Hz, \( \alpha\)-CH=), 7.45–7.42 (1H, m, C₅'-H), 2.65 (3H, s, CH₃) ppm; \(^{13}\)C NMR (100 MHz, CD₃OD): \( \delta = 165.8, 165.7, 154.1, 150.9, 138.9, 138.8, 125.6, 125.2, 114.5, 10.7 \) (CH₃) ppm; IR (ATR): \( \tilde{\nu} = 3,038, 2,162, 1,648, 1,577, 1,529, 1,476, 1,437, 1,390, 1,353, 1,324, 1,230, 1,162, 1,100, 1,041, 991, 986, 904, 792, 675, 665 cm⁻¹; UV–Vis (MeOH): \( \lambda_{\text{max}} (\varepsilon < 10^3) = 302.0 \) (21.17), 263.5 (14.13), 201.5 (9.96) nm (mol⁻¹ dm³ cm⁻¹); MS (EI, 70 eV): \( m/z (%) = 187 \) (M⁺, 40), 186 (100), 144 (12), 132 (15), 117 (17), 116 (34), 104 (12), 90 (11), 78 (14), 51 (10).

5-Phenyl-2-[2-(pyridyl)ethenyl]-1,3,4-oxadiazole

**6d, C_{10}H_{9}N_{3}O**

White solid; yield 1.29 g (69%); m.p.: 116–118 °C; \( R_f = 0.53 \) (MeOH/CHCl₃, 1:4 v/v); \(^1^H\) NMR (400 MHz, CDCl₃): \( \delta = 8.76 \) (1H, d, \( J = 2.0 \) Hz, C₂'-H), 8.61 (1H, dd, \( J = 4.8, 1.6 \) Hz, C₆'-H), 7.89 (1H, dt, \( J = 8.0, 2.0 \) Hz, C₄'-H), 7.50 (1H, d, \( J = 16.4 \) Hz, \( \beta\)-CH=), 7.37 (1H, dd, \( J = 8.0, 4.8 \) Hz, C₅'-H), 7.08 (1H, d, \( J = 16.4 \) Hz, \( \alpha\)-CH=), 2.60 (3H, s, CH₃) ppm; \(^{13}\)C NMR (100 MHz, CDCl₃): \( \delta = 163.9, 163.4, 150.6, 149.2, 134.7, 133.4, 130.5, 123.8, 112.1, 11.0 \) (CH₃) ppm; IR (ATR): \( \tilde{\nu} = 3,050, 3,019, 2,164, 1,645, 1,575, 1,524, 1,503, 1,484, 1,446, 1,419, 1,362, 1,236, 1,131, 1,051, 1,024, 967, 954, 859, 819, 800, 747, 717, 674, 664 cm⁻¹; UV–Vis (MeOH): \( \lambda_{\text{max}} (\varepsilon < 10^3) = 293.5 \) (21.38), 283.5 (21.64), 200.5 (10.05) nm (mol⁻¹ dm³ cm⁻¹); MS (EI, 70 eV): \( m/z \) (%) = 187 (M⁺, 34), 186 (100), 144 (10), 132 (12), 116 (28), 104 (11), 90 (12), 51 (10), 43 (22).

5-Phenyl-2-[2-(3-pyridyl)ethenyl]-1,3,4-oxadiazole

**6e, C_{11}H_{11}N_{3}O**

White solid; yield 1.57 g (78%); m.p.: 54–56 °C; \( R_f = 0.61 \) (MeOH/CHCl₃, 1:4 v/v); \(^1^H\) NMR (400 MHz, CDCl₃): \( \delta = 8.77 \) (1H, d, \( J = 2.0 \) Hz, C₂'-H), 8.61 (1H, dd, \( J = 4.8, 1.6 \) Hz, C₆'-H), 7.90 (1H, dt, \( J = 8.0, 2.0 \) Hz, C₄'-H), 7.50 (1H, d, \( J = 16.4 \) Hz, \( \beta\)-CH=), 7.38 (1H, dd, \( J = 8.0, 4.8 \) Hz, C₅'-H), 7.10 (1H, d, \( J = 16.4 \) Hz, \( \alpha\)-CH=), 2.94 (2H, q, \( J = 7.6 \) Hz, CH₂), 1.44 (3H, t, \( J = 7.6 \) Hz, CH₃), 1.44 (3H, t, \( J = 7.6 \) Hz, CH₃) ppm; \(^{13}\)C NMR (100 MHz, CDCl₃): \( \delta = 167.5, 163.7, 150.6, 149.3, 134.6, 133.3, 130.6, 123.8, 112.2, 19.1 \) (CH₃), 10.7 (CH₃) ppm; IR (ATR): \( \tilde{\nu} = 3,178, 3,073, 1,645, 1,570, 1,504, 1,463, 1,450, 1,412, 1,379, 1,344, 1,315, 1,248, 1,193, 1,129, 1,083, 1,024, 955, 860, 806, 792, 699, 675 cm⁻¹; UV–Vis (MeOH): \( \lambda_{\text{max}} (\varepsilon < 10^3) = 294.5 \) (22.24), 284.0 (22.31), 201.0 (11.39) nm (mol⁻¹ dm³ cm⁻¹); MS (EI, 70 eV): \( m/z \) (%) = (M⁺, 32), 200 (100), 144 (10), 132 (12), 116 (28), 104 (11), 90 (12), 51 (10), 43 (17).

5-Phenyl-2-[2-(pyridyl)ethenyl]-1,3,4-oxadiazole

**6f, C_{11}H_{11}N_{3}O**

White solid; yield 2.19 g (88%); m.p.: 169–171 °C (Ref. [68] 170–172 °C).

5-Methyl-2-[2-(3-pyridyl)ethenyl]-1,3,4-oxadiazole

**6g, C_{10}H_{9}N_{3}O**

White solid; yield 1.42 g (76%); m.p.: 118–120 °C; \( R_f = 0.55 \) (MeOH/CHCl₃, 1:4 v/v); \(^1^H\) NMR (400 MHz, CDCl₃): \( \delta = 8.67 \) (2H, d, \( J = 6.0 \) Hz, C₂'-H, C₆'-H), 7.44 (1H, d, \( J = 16.4 \) Hz, \( \beta\)-CH=), 7.40 (2H, d, \( J = 6.0 \) Hz, C₃'-H, C₅'-H), 7.20 (1H, d, \( J = 16.4 \) Hz, \( \alpha\)-CH=), 2.61 (3H, s, CH₃) ppm; \(^{13}\)C NMR (100 MHz, CDCl₃): \( \delta = 163.7, 163.6, 150.5, 141.8, 135.6, 121.2, 114.3, 11.0
5-Ethyl-2-[2-(4-pyridyl)ethenyl]-1,3,4-oxadiazole (6h, C17H11N3O2)

White solid; yield 2.34 g (94 %); m.p.: 172–174 °C; UV–Vis (MeOH): ɛ_max (ε × 10^3) = 291.0 (23.16), 282.0 (24.45), 209.5 (9.42) nm (mol⁻¹ dm³ cm⁻¹); MS (EI, 70 eV): m/z (%) = 187 (M⁺, 66), 186 (100), 132 (17), 130 (12), 117 (10), 104 (11), 90 (16), 89 (10), 78 (11), 51 (13).

5-Phenyl-2-[2-(4-pyridyl)ethenyl]-1,3,4-oxadiazole (6i, C15H13N3O)

White solid; yield 1.69 g (84 %); m.p.: 62–65 °C; Rf = 0.59 (MeOH/CHCl₃, 1:4 v/v); ¹H NMR (400 MHz, CDCl₃): δ = 8.86 (2H, d, J = 6.0 Hz, C2'-H, C6'-H), 7.44 (1H, d, J = 16.4 Hz, β-CH=), 7.40 (2H, d, J = 6.0 Hz, C3'-H, C5'-H), 7.22 (1H, d, J = 16.4 Hz, α-CH=), 2.95 (2H, q, J = 7.6 Hz, CH₂), 1.44 (3H, t, J = 7.6 Hz, CH₃) ppm; ¹³C NMR (100.6 MHz, CDCl₃): δ = 167.5, 163.9, 150.5, 141.7, 135.6, 121.2, 114.3, 19.2 (CH₂), 10.8 (CH₃) ppm; IR (ATR): 3,194, 3,082, 1,646, 1,587, 1,549, 1,502, 1,484, 1,411, 1,335, 1,291, 1,227, 1,170, 1,124, 1,099, 1,070, 1,038, 971, 918, 891, 880, 871, 821, 767, 662 cm⁻¹; UV–Vis (MeOH): ɛ_max (ε × 10^3) = 292.0 (24.28), 282.5 (25.75), 210.0 (10.18) nm (mol⁻¹ dm³ cm⁻¹); MS (EI, 70 eV): m/z (%) = 201 (M⁺, 52), 200 (100), 132 (16), 116 (23), 104 (11), 90 (14), 89 (10), 78 (21), 57 (17).

5-Phenyl-2-[2-(4-pyridyl)ethenyl]-1,3,4-oxadiazole (6j, C15H13N3O)

White solid; yield 2.34 g (94 %); m.p.: 172–174 °C; Rf = 0.67 (MeOH/CHCl₃, 1:4 v/v); ¹H NMR (400 MHz, CDCl₃): δ = 8.69 (2H, d, J = 6.0 Hz, C2'-H, C6'-H), 8.13 (2H, dd, J = 8.0, 1.6 Hz, C2''-H, C6''-H), 7.56 (1H, d, J = 16.4 Hz, β-CH=), 7.55–7.51 (3H, m, C3''-H, C5''-H, C6''-H), 7.43 (2H, d, J = 6.0 Hz, C3'-H, C5'-H), 7.29 (1H, d, J = 16.4 Hz, α-CH=) ppm; ¹³C NMR (100.6 MHz, CDCl₃): δ = 164.5, 163.3, 150.6, 141.8, 135.9, 132.0, 129.1, 127.0, 123.4, 121.2, 114.3 ppm; IR (ATR): V = 3,188, 3,062, 1,962, 1,674, 1,596, 1,555, 1,502, 1,471, 1,420, 1,356, 1,322, 1,288, 1,230, 1,178, 1,134, 1,099, 1,070, 1,038, 971, 918, 891, 880, 871, 728, 663 cm⁻¹; UV–Vis (MeOH): ɛ_max (ε × 10^3) = 307.0 (29.03), 248.0 (13.56), 202.0 (26.35) nm (mol⁻¹ dm³ cm⁻¹); MS (EI, 70 eV): m/z (%) = 249 (M⁺, 57), 248 (100), 132 (14), 105 (47), 78 (10), 77 (43), 51 (13).

X-ray crystal structure analysis for 6c and 6f

The single crystal of 5-phenyl-2-[2-(2-pyridyl)ethenyl]-1,3,4-oxadiazole (6c) and 5-phenyl-2-[2-(3-pyridyl)ethenyl]-1,3,4-oxadiazole (6f) were used for data collection at 100.0(1) K on a four-circle Oxford Diffraction Xcalibur diffractometer equipped with a two-dimensional area CCD detector using graphite-monochromatized MoKα radiation (λ = 0.71073 Å) and the o-scan technique. Integration of the intensities and correction for Lorentz and polarization effects were performed using CrysAlis RED software [69]. The crystal structures were solved by direct methods and refined by a full-matrix least-squares method on F² using the program SHELXL-97 [70].

Complete crystallographic details for 6c and 6f are available as Supplementary data (CCDC 994,076 and 994,077) and have been deposited at the Cambridge Crystallographic Data Centre (CCDC), 12 Union Road, Cambridge, CB21EZ, UK; e-mail: deposit@ccdc.cam.ac.uk or http://www.ccdc.cam.ac.uk. Any request to the CCDC for this material should quote the full literature citation.

Acknowledgments The authors thank Professor Wojciech Zielinski for stimulating discussions.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Suwitski J, Szczepankiewicz W (2008) 1,3,4-Oxadiazoles. In: Katritzky AR, Ramsden CA, Scriven EFV, Taylor RJK (eds) Comprehensive Heterocyclic Chemistry III, vol 5. Elsevier Science Ltd, Oxford, p 398
2. Palaska E, Sahin G, Kelicen N, Tugbadoru N, Altinok G (2002) IL Farmaco 57:101
3. Dogan H, Daran A, Rollas S, Sener G, Uysal MK, Gulen D (2002) Bioorg Med Chem 10:2893
4. Adelstein GW, Yen ChH, Dajani EZ, Bianchi RG (1976) J Med Chem 19:1221
5. Brown P, Best DJ, Broom NJP, Cassels R, Bhanlon PJ, Mitchell TJ, Osborne NF, Wilson JM (1997) J Med Chem 40:2563
6. Angelini I, Angelini L, Sparaco F (1969) 1,3,4-Oxadiazoles. British Patent 1,161,801, Aug 20, 1969; (1969) Chem Abstr 71:112937
7. Holla BS, Poojary KN, Bhat KS, Ashok M, Poojary B (2005) Indian J Chem 44B:1669
8. Kumar D, Sundaree S, Johnson EO, Shah K (2009) Bioorg Med Chem Lett 19:4492
9. El-Emam AA, Al-Deeb OA, Al-Omar M, Lehmann J (2004) Bioorg Med Chem 12:5107
10. El-Sayeda WA, El-Essawyb FA, Alib OM, Nasr BS, Abdalla MM, Abdel-Rahman AA (2009) Z Naturforsch 64C:773
11. Zheng X, Li Z, Wang Y, Chen W, Huang Q, Liu C, Song G (2003) J Fluorine Chem 123:163
12. Zou XJ, Lai LH, Zhang ZX (2002) J Agric Food Chem 50:3757
13. Schulz B, Orgzall I, Freydank A, Xii C (2005) Adv Colloid Interface Sci 116:143
14. Chen ZK, Meng H, Lai YH, Huang W (1999) Macromolecules 32:4351
15. Tamoto N, Adachi C, Nagai K (1997) Chem Mater 9:1077
16. Sinigersky V, Wegner G, Schopov I (1993) Eur Polym J 29:617
17. Ainsworth C (1955) J Am Chem Soc 77:1148
18. Tully WR, Cardner CR, Gillespie RJ, Westwood R (1991) J Med Chem 34:2060

© Springer
19. Short FW, Long LM (1969) J Heterocycl Chem 6:707
20. Kerr NV, Ott DG, Hayes FN (1960) J Am Chem Soc 82:186
21. Al-Talib M, Tashtoush H, Odeh N (1990) Synth Commun 20:1811
22. Klinsberg E (1958) J Am Chem Soc 80:5786
23. Theocharis AB, Alexandrou NE (1990) J Heterocycl Chem 27:1685
24. Carlsen HJ, Jorgensen KB (1994) J Heterocycl Chem 31:805
25. Liras S, Allen MP, Segelstein BE (2000) Synth Commun 30:437
26. Tandon VK, Chhor RB (2001) Synth Commun 31:1727
27. Brain CT, Paul JM, Loong Y, Oakley PJ (1999) Tetrahedron Lett 40:3275
28. Dabiri M, Salehi P, Baghbanzadeh M, Bahramnejad M (2006) Tetrahedron Lett 47:6983
29. Rostamizadeh S, Ghasem Housaini SA (2004) Tetrahedron Lett 45:8753
30. Shang Z, Reiner J, Chang J, Zhao K (2005) Tetrahedron Lett 46:2701
31. Prabhu G, Bucherri F, Noto R, Gentile M (1977) J Heterocycl Chem 14:1385
32. Xia Y, Liu J, Yang P, Shi X, Li J (2011) Tetrahedron 67:5369
33. Theocharis AB, Alexandrou NE (1990) J Heterocycl Chem 27:1685
34. Tandon VK, Chhor RB (2001) Synth Commun 31:1727
35. Brain CT, Paul JM, Loong Y, Oakley PJ (1999) Tetrahedron Lett 40:3275
36. Wipf P, Venkatraman S (1996) Tetrahedron Lett 37:4659
37. Coppo FT, Evans KA, Graybill TL, Burton G (2004) Tetrahedron Lett 45:3257
38. Kudelko A, Jasiak K (2013) Synthesis 45:1950
39. Schneider C, Mass D, Coute-Bonne S, Panneconu X, Huo- rau C (2013) Angew Chem Int Ed 52:3246
40. Detert H, Schollmeier D (1999) Synthesis 999
41. Borecka B, Ito Y, Olofsson G, Scheller J, Trotter J (1995) Tetrahedron Lett 36:6087
42. Aoyama H, Hashimoto M, Hashimoto Y, Ishikawa M, Tetsuhashi M (2010) Bioorg Med Chem 18:5323
43. Lifke T, Meier H (1995) J Prakt Chem/Chem Ztg 337:641
44. Beyerman HC, Bontekoe JS, Van Der Burg WJ, Veer WLC (1954) Rec Trav Chim Pays-Bas 73:109
45. Yamamori T, Nagata K, Ishizuka N, Hayashi K (2001) New use of olefin derivatives. Japan Patent 131,151, May 15, 2001; (2001) Chem Abstr 134:348270
46. Oxford Diffraction (2008) CrysAlis CCD and CrysAlis RED. Versions 1.171.32.29, Oxford Diffraction Ltd: Abingdon, Oxfordshire, England
47. Sheldrick GM (2008) Acta Crystallogr A64:112
48. Shaker RM, Mahmoud AF, Abdel-Latif FF (2005) Phosphorus-Sulfur Silicon 180:397
49. Zarghi A, Hajimahdi Z, Mohabibi S, Rashidi H, Mozaffari S, Sarraf S, Faizi M, Tabatabae SA, Shafiee A (2008) Chem Pharm Bull 56:509
50. Xie Y, Liu J, Yang P, Shi X, Li J (2011) Tetrahedron 67:5369
51. Buscemi S, Pace A, Pibiri I, Vivona N (2002) J Org Chem 67:6253
52. Brown BJ, Clemens IR, Nesses JX (2002) Synlett 131:369
53. Brain CT, Brunton SA (2001) Synlett 382
54. Brain CT, Paul JM, Loong Y, Oakley PJ (1999) Tetrahedron Lett 40:3275
55. Wipf P, Venkatraman S (1996) Tetrahedron Lett 37:4659
56. Cuppo FT, Evans KA, Graybill TL, Burton G (2004) Tetrahedron Lett 45:3257
57. Kudelko A, Jasiak K (2013) Synthesis 45:1950
58. Schneider C, Mass D, Coute-Bonne S, Panneconu X, Hou- rau C (2013) Angew Chem Int Ed 52:3246
59. Detert H, Schollmeier D (1999) Synthesis 999
60. Wang C, Jung GY, Hua Y, Pearson C, Bryce MR, Petty MC, Batsanov AS, Goeta AE, Howard JAK (2001) Chem Mater 13:1167
61. Albert A, Serjeant EP (1962) Ionization Constants of Acids and Bases. Methuen&Co Ltd, New York, p 69
62. Hoodman NS, Hawthorne JO, Masciantonio PX, Simon AW (1974) Pyridine and its Derivatives, Supplement, Part One. In: Abramovitch RA (ed), Chemistry of Heterocyclic Compounds, vol 14. John Wiley & Sons, New York, p 96
63. King JA, Hofmann V, McMillan FH (1951) J Org Chem 16:1100
64. Borecka B, Ito Y, Olofsson G, Scheller J, Trotter J (1995) Tetrahedron Lett 36:6087
65. Aoyama H, Hashimoto M, Hashimoto Y, Ishikawa M, Tetsuhashi M (2010) Bioorg Med Chem 18:5323
66. Lifke T, Meier H (1995) J Prakt Chem/Chem Ztg 337:641
67. Beyerman HC, Bontekoe JS, Van Der Burg WJ, Veer WLC (1954) Rec Trav Chim Pays-Bas 73:109
68. Yamamori T, Nagata K, Ishizuka N, Hayashi K (2001) New use of olefin derivatives. Japan Patent 131,151, May 15, 2001; (2001) Chem Abstr 134:348270
69. Oxford Diffraction (2008) CrysAlis CCD and CrysAlis RED. Versions 1.171.32.29, Oxford Diffraction Ltd: Abingdon, Oxfordshire, England
70. Sheldrick GM (2008) Acta Crystallogr A64:112

Synthesis of 1,3,4-oxadiazoles

123